Abstract The mevalonate pathway is a metabolic pathway responsible for synthesizing prenyl (both farnesyl and geranylgeranyl) groups and activating small GTPase proteins through transfer of these groups by covalent modification. These GTPase proteins include RhoA, RhoC, Rac and Cdc42, which regulate the actin cytoskeleton during cellular migration and are over-expressed in many cancers. This project explores the effects of three mevalonate pathway inhibitors–zoledronic acid, atorvastatin and geranylgeranyl transferase inhibitor (GGTI)–on the single-cell motility, collective cell migration and invasion of an aggressive breast cancer line (MDA-MB-231) and an inflammatory breast cancer derived (IBC) line (SUM149). We are using MCF10A immortalized breast cells as our “normal-like” control. We hypothesize that these cancers rely on this pathway for cellular motility, invasion and the structure of the actin cytoskeleton more than normal epithelial cells. We observed significant decreases in total quantities of Rac, RhoC and Cdc42 and a striking increase in RhoA upon treatment with each separate inhibitor, observed by western blot. The effect is much more potent with atorvastatin and GGTI, resulting in an almost complete loss of lamellipodia and filopodia. We assayed for invasion through 3D culture transwell chambers, individual cell motility using a bead motility assay and live-cell imaging, and collective cell migration using a wound healing assay. In general, all three drugs were highly effective at inhibiting both types of cell migration and invasion in MDA-MB-231 cells. While all drugs inhibited the collective cell migration of SUM149 cells, only GGTI additionally inhibited invasion and single cell migration. This result suggests that an approach targeting geranylgeranylation may be more effective for inhibition of IBC cells. Typically IBC tumors use collective cell migration mechanisms to metastasize, whereas MDA-MB-231 tumors metastasize through single-cell migration. Our results show that aggressive breast cancers heavily rely on the mevalonate pathway for cellular motility in comparison to normal epithelial cells, and that inhibitors of this pathway have significant potential to inhibit the metastatic properties of these two tumor types, given their mechanism of tissue invasion. We are continuing to study collective cell movement by assaying for cell-cell adhesion molecules upon treatment with our three inhibitors. In addition, we are studying the effects of these inhibitors on metastasis in vivo using xenograft mouse models and Her2Neu transgenic mouse models. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1397. doi:10.1158/1538-7445.AM2011-1397
Read full abstract